"Gilead's Stock Plummets as Lung Cancer Treatment Trial Disappoints"
Gilead Sciences' stock plunges over 10% in premarket trading after disappointing trial results for its lung cancer treatment, Trodelvy, failing to meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer. The company plans to discuss the results with regulators, expressing continued confidence in Trodelvy's potential in metastatic NSCLC despite the setback.